French Generics Pharma Manufacturers (2026)

French generics manufacturers sit on a market that produces 3.5 billion boxes of medicine a year out of 271 industrial sites, but most of them still find international buyers through the same trade fair and tender channels they used a decade ago. The sector has one dominant player, a handful of multinationals running French plants, and a long bench of CDMOs filling private-label molecules for everyone else. The opportunity in 2026 is clear. Reshoring money is moving, drug shortages have rewritten procurement priorities across Europe, and generics buyers are actively looking for non-Asian suppliers. The bottleneck is sales pipeline.

The shape of the French generics market in 2026

France runs second only to Germany as Europe’s biggest drug manufacturer. According to the CDMO France association, the country has 271 pharmaceutical production sites, employs roughly 100,000 people, and turned over USD 46.5 billion in 2023. The industrial base also halved between 2005 and 2023, which is why the French government is now writing cheques to bring production home.

Generics specifically punch below their weight. They represent 42% of the prescription market by volume excluding paracetamol, compared with around 80% in Germany, Canada, and the Netherlands, per GaBI Online’s France country focus. That gap is what makes the French market structurally different from its neighbours. Penetration is lower, prices are lower, and the political pressure to reshore production is higher.

One company dominates. Biogaran, until October 2025 the generics arm of Servier and now owned by BC Partners and Bpifrance, holds a 32% share of the French reimbursed generics market with 356 million boxes sold a year, 1,078 different references in its portfolio, and EUR 1.122 billion in net statutory revenue for 2023 to 2024. Biogaran outsources 100% of its production. 89% is made in Europe and just under 50% in France itself, which means hundreds of CDMOs and CMOs across the country live or die on contracts from a single buyer.

The rest of the field looks like this. Mylan/Viatris France runs commercial operations and packaging out of multiple French sites. Sandoz France (part of the Novartis spinoff) is the second-largest generics supplier in pharmacies. Teva France, Zentiva France, EG Labo, Cristers, and Arrow Génériques (acquired by Aurobindo) fill out the top ten. None of these companies make their own molecules at scale in France. They source from CDMOs, repackage, and sell into reimbursement.

The CDMOs are where the manufacturing actually happens. Delpharm, Fareva, Unither Pharmaceuticals, and Recipharm France are the four largest, and they belong to a CDMO France association covering 24 subcontractors across 80 industrial sites. Delpharm alone inaugurated a new Annex 1 compliant sterile filling line at Saint Remy in June 2025, a EUR 37 million investment adding 45 million units of capacity in 2 ml format. Fareva put more than EUR 30 million into modernising sterile capabilities in the same window.

Why 2026 is different: reshoring, shortages, and money on the table

Three things changed in the last two years that French generics manufacturers should be using to open conversations with international buyers.

First, reshoring is funded, not just announced. France launched its plan to reshore production of essential medicines in June 2023. The Ministry of Health drew up a list of 450 essential medicines, of which 50 were flagged for domestic production reinforcement or restart, per Van Bael & Bellis. 14 industrial projects are backed by France 2030 with nearly EUR 300 million in committed investment. The wider France 2030 health envelope is EUR 7.5 billion, with EUR 800 million ring-fenced for biotherapies and biomanufacturing. The PLFSS 2026 also includes language encouraging preferential treatment for drugs produced locally, which feeds directly into CEPS price negotiations.

Second, drug shortages have changed how procurement teams think. The European Court of Auditors Special Report 19/2025 found that EU countries ran critically short of 136 medicines between January 2022 and October 2024. The European Commission proposed a new Critical Medicines Act in March 2025 to boost EU manufacturing capacity. France has gone further nationally, increasing fines for stockouts and requiring companies to hold safety stocks covering at least two months of domestic demand for medicines of major therapeutic interest. For generics manufacturers, this is the procurement narrative that opens doors. European buyers want non-Asian suppliers, EU-based redundancy, and the ability to prove continuity of supply.

Third, the margin pressure is real, but so is the pricing arbitrage. GEMME (the French generics association, recently renamed ALMA) flagged that generic prices in France are roughly 41% lower than in Germany, Italy, Spain, and the UK, at EUR 0.16 per tablet against EUR 0.27 on average. As Catherine Bourrienne-Bautista, GEMME’s Director, put it: “If we are to increase the level of production taking place in France, we need to ensure that there are no more price cuts because if they are cut anymore the margins will be too small.” For a French manufacturer with EUR 0.16 per tablet domestic prices, exporting to Germany, the UK, or Italy at closer to EUR 0.27 is structurally accretive, before any volume effects.

Thierry Hulot, president of LEEM, summarised the political moment in a LEEM tribune: “We, pharmaceutical companies, firmly believe that a France that is an industrial champion in health is an achievable ambition.” For more context on how this fits the wider French pharma export landscape, see our overview of French pharma and biotech manufacturers.

The traditional sales channels are saturating fast

French generics and CDMOs have run the same outbound playbook for two decades. Each channel is hitting a ceiling.

Trade fairs are still booked, still expensive, still not generating enough qualified pipeline. CPHI Worldwide is the largest event in the sector, with thousands of CDMOs, API suppliers, packagers, and buyers in attendance. A 9 square metre booth runs EUR 12,000 to EUR 25,000 before travel, sample logistics, and staff time. Pharmapack Europe in Paris is the standard event for packaging and drug delivery. World Generic Medicines Congress in Amsterdam is the dedicated generics show. The economics have not held up. You meet whoever walks past the booth, mostly procurement officers gathering quotes rather than R&D leads or regulatory directors with budget authority. Cost per qualified lead consistently runs EUR 300 to EUR 900+ and scales linearly with booth size and headcount.

Government tenders and hospital group buying offices are slower than ever. CEPS in France, national health authority listings across Europe, hospital group purchasing organisations, and central tenders all share the same problem. Procurement cycles are 12 to 24 months, price is the dominant lever, and once you are listed you compete on cents per tablet against suppliers from India and China. For a French CDMO that wants direct relationships with branded generics buyers rather than commodity tender flow, this channel is structurally limited.

GAVI, UNICEF, WHO bidding works for very large generics players with WHO prequalified products and the back office to handle international donor logistics. For mid-size French generics manufacturers, the volumes are interesting but the qualification process is a separate full-time function.

Distributor lock-in. Many French CDMOs sell into Europe and North Africa through long-standing distributor relationships. The distributor owns the customer, takes 15 to 30 points of margin, and when a procurement decision turns on a cheaper alternative the manufacturer is the last to know.

Field sales representatives with pharma chemistry credibility cost EUR 90,000 to EUR 160,000 fully loaded per market in Europe. Covering Germany, the UK, Italy, Spain, and Benelux means five reps with five different regulatory profiles. Cost per qualified lead at scale: EUR 500 to EUR 1,200+, and it scales worse than linearly because the talent is scarce.

Cold calling done in the buyer’s language by an experienced SaaS-style seller still works. The problem is finding people who can hold a technical conversation about bioequivalence, GMP audits, and CEP filings, in German, Italian, or Polish, at a price that does not destroy unit economics. Almost no French generics manufacturer has that team in-house across more than one or two languages.

What an AI-powered outbound engine actually does for a French generics manufacturer

papaverAI builds outbound engines for B2B manufacturers. For a generics manufacturer or CDMO, that means an engine that does five things on repeat, in parallel, across every target country.

It identifies the right buyers at the right accounts. Not procurement officers browsing CPHI, but the regulatory affairs directors, quality heads, product portfolio managers, and supply chain leads who make supplier qualification decisions for generics and APIs.

It writes in the buyer’s native language at the level a senior procurement leader expects. German to German buyers, Italian to Italian buyers, English to UK and Nordic buyers, Spanish to Spanish and Latin American buyers.

It runs sequenced outreach across email and LinkedIn with proper deliverability infrastructure, so that messages land in the inbox rather than spam, and so the manufacturer’s main domain is never exposed to outbound volume.

It handles replies, qualifies them, and routes positive responses to a senior person at the manufacturer for the human conversation that actually closes deals. No bot handoffs to prospects. Humans take the meeting.

It learns. Every reply, every meeting booked, every deal won feeds back into targeting, messaging, and timing. The system gets cheaper and more accurate over time.

Cost per qualified lead starts at USD 150 to USD 300 depending on sector and geography, and compounds downward as the engine accumulates feedback. Trade fairs scale linearly. Field sales scale worse than linearly. An AI outbound engine has a compounding floor. For more on how the engine actually works, see How It Works or our Growth Engine page.

Where French generics manufacturers should look first

The same engine works across multiple buyer profiles. The highest-value targets in 2026 for a French generics manufacturer or CDMO are:

Branded generics companies in Germany, Italy, Spain, the UK, and the Nordics looking for EU-based alternative suppliers as they de-risk Asian dependency. Procurement teams here are explicitly mandated to find non-Asian suppliers after the 2022 to 2024 shortage wave.

Hospital pharmacy networks and private hospital groups across Europe with their own dispensing operations and buying autonomy. These are smaller volumes per account than central tenders but with much faster decision cycles.

Specialty pharmacy chains in markets where they are growing share, particularly Germany and the UK.

Veterinary pharma and OTC players in adjacent categories that need contract manufacturing capacity for sterile injectables, soft gels, and oral solids.

Biotech and small molecule innovators in the UK, Switzerland, and the Nordics looking for European fill-and-finish or commercial scale manufacturing partners. Adjacent to generics but a higher-margin segment for CDMOs.

For broader context on how French manufacturing exporters are using AI outbound across sectors, see our France manufacturing exports overview.

FAQ

Who are the largest generics manufacturers in France?

Biogaran is the clear leader with a 32% share of the French reimbursed generics market and 356 million boxes sold a year, per Servier’s Biogaran fact sheet. Sandoz France, Mylan/Viatris France, Teva France, Zentiva France, EG Labo, Cristers, and Arrow Génériques fill out the top ten. The actual manufacturing happens largely at French CDMOs including Delpharm, Fareva, Unither, and Recipharm France.

What share of medicines used in France are generics?

Generics represent roughly 42% of the prescription market by volume excluding paracetamol, according to GaBI Online. That is below the 80% seen in Germany, Canada, and the Netherlands. The penetration gap is one reason the French government is pushing both for higher generic substitution rates and for more domestic generics production.

How is France reshoring generics production?

France 2030 has backed 14 industrial projects with nearly EUR 300 million in committed investment specifically to reinforce or restart domestic production of 50 essential medicines, per Van Bael & Bellis. The PLFSS 2026 also includes language encouraging CEPS to give preferential treatment in price negotiations to drugs produced locally.

Why are drug shortages relevant to French generics exporters?

The European Court of Auditors reported that EU countries ran critically short of 136 medicines between January 2022 and October 2024. Procurement teams across Europe are now actively mandated to find EU-based alternative suppliers and to build redundancy outside Asia. French manufacturers with GMP-certified sites and EU regulatory status are well-positioned for that conversation.

What is the cost per qualified lead for trade fairs versus AI outbound?

Trade fairs in pharma typically cost EUR 300 to EUR 900+ per qualified lead and scale linearly with booth size. Field sales reps cost EUR 500 to EUR 1,200+ per qualified lead and scale worse than linearly because pharma-credible reps are scarce. AI outbound engines start at USD 150 to USD 300 per qualified lead and get cheaper as the engine learns. The structural difference matters more than the headline number.

Can French CDMOs use the same outbound engine to find international clients?

Yes. The buyer profile shifts from procurement teams at branded generics buyers to business development directors and supply chain leads at innovator pharma and other branded generics companies. The engine identifies the right contacts, writes in their language, and books meetings. The CDMO’s commercial team takes the conversations.

If you want to talk about how this would work for your generics or CDMO business, get in touch or read more about our Growth Engine.